Mounjaro typically leads to an average of around 15% weight loss
The medication doesnt impair physical performance
[90] In March 2026, the CHMP recommended granting a conditional marketing authorization for Kayshild (semaglutide), a GLP-1 receptor agonist for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis, a serious disease where fat deposits accumulate in the liver causing inflammation
Compounding allows for flexible dosing and cost accessibilityat $189/mo month-to-month, or from $149/mo on the 6-month plan with no insurance required
In contrast, Wegovy has a shorter window of only 28 days at similar temperatures
The Benefits of GLP-1 Agonist within a Supervised Program Incorporating GLP-1 Agonist into a structured weight management plan at Allure Medical can offer significant benefits: Clinically Proven Weight Loss: Achieve substantial weight loss, often significantly more than with diet and exercise alone (studies show averages around 15% body weight loss)